The therapeutic community is excited with anticipation surrounding retatrutide, a innovative dual GIP and GLP-1 agonist that’s showing significant potential in clinical trials for addressing obesity. Unlike some available weight loss treatments, retatrutide appears to provide a significant substantial reduction in body mass and enhance metabolic